Lacosamide Sandoz (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons. This stabilizes the inactive state of the channels, limiting repetitive firing and decreasing neuronal hyper‑excitability that contributes to seizure generation.

The specific dose of Lacosamide Sandoz is determined by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Dosage adjustments may be needed for renal or hepatic impairment, and the prescriber will provide individualized instructions.

Safety data for lacosamide in pregnancy and lactation are limited, and the pregnancy category is listed as unknown. Clinicians should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lacosamide belongs to the sodium channel blocker class, offering a distinct mechanism that enhances slow inactivation of sodium channels. Compared with drugs that target fast inactivation (e.g., carbamazepine), lacosamide may have a different side‑effect profile and can be useful when other agents are ineffective or not tolerated.

Lacosamide Sandoz tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Lacosamide Sandoz is taken orally, usually as a tablet, with or without food. The exact administration schedule is set by the prescriber, who may recommend taking the dose at the same time each day to maintain consistent blood levels.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, potential suicidal thoughts or behaviors, severe skin reactions like Stevens‑Johnson syndrome, hypersensitivity reactions, hepatic injury, and rare cases of rhabdomyolysis. Patients should be monitored for these events, especially during treatment initiation.

Lacosamide Sandoz is contraindicated in patients with known hypersensitivity to lacosamide or any of its excipients. Caution is advised for individuals with significant cardiac conduction disorders, severe hepatic impairment, or those taking interacting medications that could markedly reduce its effectiveness.